Table 1

Patient characteristics

Patients

N = 29


Median age (range) - yrs

59 (26 -- 80)

Gender -- no. (%)

Male (%)

15 (52.0)

Female (%)

14 (48.0)

ECOG performance status -- no. (%)

0

11 (37.9)

1

17 (58.6)

2

1 (3.5)

Primary tumor site -- no. (%)

Pancreas

13 (44.8)

Functioning

5 (17.2)

Unknown

7 (24.2)

Small bowel

7 (24.2)

Appendix

1 (3.4)

Colon

1 (3.4)

Tumor Stage -- no. (%)

Locally advanced/metastatic

2/27

Site of metastases -- no. (%)

< 2 sites

13 (44.8)

≥ 2 sites

16 (55.2)

Prior therapies -- no. (%)

Surgery

9 (31.0)

Progressive disease

29 (100)

Baseline symptoms -- no. (%)

Diarrhea

6 (20.6)

Flushing

4 (13.8)

Carcinoid syndrome

4 (13.8)

Hypoglycemia

2 (6.9)

Others

10 (34.5)

Circulating chromogranin A levels (U/L) - no. (%)

Normal levels

4 (13.8)

Supranormal levels

25 (86.2)

Histological tumor characteristics -- no. (%)

SST2

1+

2 (9.1)

2+

8 (36.4)

3+

12 (54.5)

missing

7

Mitosis (per square millimeter)

< 2

17 (68.0)

2 -- 20

7 (28.0)

> 20

1 (4.0)

missing

4

Ki67

≤ 2%

11 (42.3)

3 -- 10%

13 (50.0)

> 10%

2 (7.7)

missing

3

VEGF

0

3 (15.8)

1

4 (21.1)

2

7 (36.8)

3

5 (26.8)

missing

10


SST2 = somatostatin receptor type 2

VEGF = vascular endothelial growth factor

Brizzi et al. BMC Cancer 2009 9:388   doi:10.1186/1471-2407-9-388

Open Data